- Report
- March 2025
- 175 Pages
Global
From €4240EUR$4,490USD£3,607GBP
- Report
- March 2025
- 200 Pages
Global
From €4240EUR$4,490USD£3,607GBP
- Report
- May 2024
- 139 Pages
Global
From €6138EUR$6,499USD£5,220GBP
- Report
- August 2024
- 150 Pages
Global
From €2634EUR$2,789USD£2,240GBP
- Report
- August 2020
- 250 Pages
Saudi Arabia
From €3060EUR$3,240USD£2,603GBP
€3400EUR$3,600USD£2,892GBP
- Report
- January 2024
- 200 Pages
Global
From €3919EUR$4,150USD£3,334GBP
- Report
- February 2024
- 110 Pages
Global
From €4486EUR$4,750USD£3,815GBP
- Report
- April 2023
- 91 Pages
Global
From €3500EUR$3,970USD£3,081GBP
- Report
- April 2025
- 50 Pages
Global
From €2503EUR$2,650USD£2,129GBP
- Report
- April 2025
- 50 Pages
Global
From €2503EUR$2,650USD£2,129GBP
Pioglitazone is a drug used to treat type 2 diabetes, a condition in which the body does not produce enough insulin or does not use insulin properly. It belongs to a class of drugs known as thiazolidinediones, which work by increasing the body's sensitivity to insulin. Pioglitazone is used in combination with diet and exercise to improve glycemic control in adults with type 2 diabetes. It can also be used to reduce the risk of cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
Pioglitazone is a widely used drug in the endocrine and metabolic disorders drug market. It is used to treat type 2 diabetes, a condition that affects millions of people worldwide. Pioglitazone is generally well tolerated and has been shown to improve glycemic control and reduce the risk of cardiovascular events in adults with type 2 diabetes.
Some companies in the pioglitazone market include Takeda Pharmaceuticals, Merck & Co., Sanofi, and Eli Lilly. Show Less Read more